CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 900 target
Drug / intervention
Immune Globulin Intravenousbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07202065
NCT07202065Phase 3RecruitingHigh MomentumUpdated 8mo ago

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy (Dose-Ig)

Monash University·interventional·Posted Oct 1, 2025·Updated Oct 7, 2025

In Brief

A Phase 3 clinical trial evaluating Immune Globulin Intravenous for Myeloma and 2 related conditions. Currently recruiting, targeting 900 participants across 3 sites.

Signals

Enrolling ahead of pace

Detailed Summary

This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers. The best way to find out this information is to directly compare the effect of different treatment strategies in patients with blood cancers. We want to know how these different treatments impact on your health and your use of healthcare services. This research project uses an Adaptive Platform Design. This design allows the researchers to compare multiple infection prevention strategies within the same trial at the same time (rather than running separate trials), to analyse results as the trial occurs and to add new research questions during the course of the trial. The treatments that you may receive as part of the study will be determined by which domain(s) of the platform you participate in. By combining data collected within each domain as part of the platform, the researchers can investigate and compare treatment strategies and infection outcomes across a broader range of participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia
Collaborators--

Timeline

Phase 3Recruiting
20262027
First PostedOct 1, 2025
Enrollment StartApr 28, 2025
Primary CompletionMar 31, 2027
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 9 months agoPrimary completion in 9 months

Interventions

Immune Globulin Intravenousbiological

Participants will be treated with intravenous immunoglobulin monthly (every 4 weeks ± 1 week).